

S5 Table. Comparison of clinical characteristics between genomic groups.

Clinical characteristic	No. (%)			p-value
	Group (n=117)	1 Group (n=24)	2 Group (n=17)	
Age at metastasectomy, mean±SE (yr)	60.2±1.0	61.8±2.2	65.6±3.0	0.169
Sex				0.210
Male	73 (62.4)	16 (66.7)	7 (41.2)	
Female	44 (37.6)	8 (33.3)	10 (58.8)	
Initial stage				0.003
I or II	17 (14.5)	34 (29.1)	66 (56.4)	
III	4 (16.7)	11 (45.8)	9 (37.5)	
IV	9 (52.9)	4 (23.5)	4 (23.5)	
Type of metastasis				0.029
Synchronous	59 (50.4)	9 (37.5)	3 (17.6)	
Metachronous	58 (49.6)	15 (62.5)	14 (82.4)	
Primary site				0.007
Rectum	60 (51.3)	13 (54.2)	7 (41.2)	
Left colon	46 (39.3)	4 (16.7)	4 (23.5)	
Right colon	11 (9.4)	7 (29.2)	6 (35.3)	
Metastatic site				>0.99
Liver	71 (60.7)	14 (58.3)	10 (58.8)	
Lung and other	46 (39.3)	10 (41.7)	7 (41.2)	
Overall metastatic site				0.136
Liver only	50 (42.7)	8 (33.3)	4 (23.5)	
Lung only	28 (23.9)	3 (12.5)	3 (17.6)	
Both liver and lung	22 (18.8)	6 (25.0)	3 (17.6)	
Others	17 (14.5)	7 (29.2)	7 (41.2)	
Sum of diameter for metastatic lesions at metastasectomy, mean±SE (mm)	34.9±4.1	19.4±2.0	26.5±3.5	0.175
Response to treatment after metastasectomy				0.488
Complete response	59 (50.4)	9 (37.5)	9 (52.9)	
Recurrence or progressive disease	58 (49.6)	15 (62.5)	8 (47.1)	